GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DRI Healthcare Trust (OTCPK:DHTRF) » Definitions » Notes Receivable

DHTRF (DRI Healthcare Trust) Notes Receivable : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is DRI Healthcare Trust Notes Receivable?

DRI Healthcare Trust's Notes Receivable for the quarter that ended in Dec. 2024 was $0.0 Mil.


DRI Healthcare Trust Notes Receivable Historical Data

The historical data trend for DRI Healthcare Trust's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DRI Healthcare Trust Notes Receivable Chart

DRI Healthcare Trust Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

DRI Healthcare Trust Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DRI Healthcare Trust Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


DRI Healthcare Trust Notes Receivable Related Terms

Thank you for viewing the detailed overview of DRI Healthcare Trust's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


DRI Healthcare Trust Business Description

Traded in Other Exchanges
Address
100 King Street West, 1 First Canadian Place, Suite 7250, Toronto, ON, CAN, M5X 1B1
DRI Healthcare Trust is engaged in pharmaceutical royalty monetization by providing capital to inventors, academic institutions, and biopharma companies. Trust was formed to provide Unitholders with differential exposure to the pharmaceutical and biotechnology industries through ownership and acquisitions of pharmaceutical royalties. In return for providing capital to biopharmaceutical innovators, the company is building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically the trust generates it's key revenue from the United States. The trust also generates Income from markets such as Japan, and the European Union.